Tani Joji

タニジョウジ | Tani Joji

Affiliation and department：

Research field (1)： Gastroenterology

Research keywords (3)：肝硬変 , 肝がん , 肝疾患

Research theme for competitive and other funds (7)：

2022 - 2025 NASH肝線維化進展におけるRAGEの役割解明とNASH肝線維化マーカー開発
2022 - 2025 Examination of the effect of combination therapy of galectin-9 and epigallocatechin gallate on hepatocellular carcinoma
2020 - 2024 腸肝軸に着目したNASHの新たな診断方法と創薬についての基礎的研究
2017 - 2020 Identification of microRNAs that regulate Galectin 9 to suppress nonalcoholic steatohepatitis progression
2016 - 2019 Basic study on treatment of hepatocellular carcinoma targetted of Gal-9 exosomes

Show all

Papers (345)：

Kyoko Oura, Asahiro Morishita, Rie Yano, Takushi Manabe, Kei Takuma, Mai Nakahara, Tomoko Tadokoro, Koji Fujita, Shima Mimura, Joji Tani, et al. Circulating miR-485-3p as a biomarker for VEGF-associated therapeutic response to atezolizumab plus bevacizumab in hepatocellular carcinoma. Journal of gastroenterology. 2025
Takushi Manabe, Chikara Ogawa, Takashi Tamada, Naoki Yoshioka, Takehiro Akahane, Hideki Fujii, Hirotaka Arai, Kei Takuma, Mai Nakahara, Kyoko Oura, et al. Usefulness of Repeated Lusutrombopag Administration in Clinical Practice and its Correlation with the Simulation Software-Predicted Platelet Count: A Multicenter Study. Internal medicine (Tokyo, Japan). 2025
Tomoko Aoki, Masatoshi Kudo, Naoshi Nishida, Kazuomi Ueshima, Kaoru Tsuchiya, Toshifumi Tada, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, et al. Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study. Journal of gastroenterology. 2025
Norikazu Tanabe, Issei Saeki, Kenji Yamaoka, Tomokazu Kawaoka, Tetsu Tomonari, Joji Tani, Takeshi Terashima, Yusuke Kawamura, Shiro Oka, Tetsuji Takayama, et al. Efficacy of Lenvatinib and Atezolizumab Bevacizumab Combination Therapy in Patients With Combined Hepatocellular-cholangiocarcinoma. Anticancer research. 2025. 45. 3. 1117-1125
Shigeo Shimose, Issei Saeki, Takanori Ito, Yasuto Takeuchi, Joji Tani, Tetsu Tomonari, Ryu Sasaki, Kyo Sasaki, Satoru Kakizaki, Takeshi Hatanaka, et al. The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan. Hepatology international. 2025

ｍore...

MISC (223)：

大濱日出子, 大濱日出子, 多田俊史, 畑中健, 谷丈二, 石川達, 糸林詠, 田尻和人, 越智裕紀, 高口浩一, et al. 切除不能肝細胞癌に対するDurvalumab+Tremelimumab療法の予後予測におけるgeriatric nutritional risk indexを用いたスコアの有用性. 肝臓. 2024. 65. Supplement 3
大濱日出子, 平岡淳, 多田俊史, 畑中健, 谷丈二, 高口浩一, 糸林詠, 柿崎暁, 厚川正則, 福西新弥, et al. 肝予備能・腫瘍進行度・腫瘍マーカーによるAtezolizumab+Bevacizumab療法の予後予測スコアーの提唱. 肝臓. 2023. 64. Suppl.2. A646-A646
Asahiro Morishita, Joji Tani, Tsutomu Masaki. Unusual pedunculated gastric polypoid lesion. Frontline Gastroenterology. 2021. 12. 7. 698-699
田所智子, 谷丈二, 正木勉, 中原麻衣, 大浦杏子, 藤田浩二, 森下朝洋. 免疫チェックポイント阻害剤投与に起因する自己免疫性肝疾患の臨床的特徴. 肝臓. 2021. 62. Supplement 1
田所智子, 谷丈二, 正木勉, 中谷夏帆, 中原麻衣, 大浦杏子, 藤田浩二, 森下朝洋. 免疫チェックポイント阻害薬投与後肝障害の臨床的検討. 日本消化器病学会雑誌(Web). 2021. 118

ｍore...

Lectures and oral presentations (2)：

肝硬変合併門脈血栓症に対してエドキサバン投与による血栓溶解の有効性,安全性
IFN-Free直接作用型抗ウイルス薬によるSVR例の新規発癌の検討-多施設共同研究-

Education (2)：

- 2013 Kagawa University Graduate School of Medicine
1996 - 2002 Kagawa University Faculty of Medicine School of Medicine

Professional career (1)：

医学博士 (香川大学)

Work history (7)：

2024/10 - 現在香川大学医学部地域医療総合医学講座特任教授
2024/04 - 2024/09 香川大学医学部消化器・神経内科講師
2019/04 - 2024/03 Kagawa University Faculty of Medicine
2017/04 - 2019/03 屋島総合病院内科部長
2010/04 - 2017/03 Kagawa University Faculty of Medicine

Show all

Association Membership(s) (4)：

THE JAPANESE SOCIETY OF INTERNAL MEDICINE , JAPAN GASTROENTEROLOGICAL ENDOSCOPY SOCIETY , JAPANESE SOCIETY OF GASTROENTEROLOGY , 日本肝臓学会

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page